Connect with us


Alcon to Acquire Eysuvis Drops for Dry Eye Treatment

Alcon will pay $60M in upfront consideration.




GENEVA — Alcon has signed an agreement to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals Inc.

The acquisition of the eye drops (0.25% loteprednol etabonate suspension) “will complement Alcon’s existing portfolio in the large and fast-growing dry eye category,” according to a press release.

Alcon will pay $60 million in upfront consideration to Kala. Alcon “may be required to make additional contingent payments upon achievement of certain commercial milestones,” according to the release.

The transaction is anticipated to close in the third quarter.

More from the release:

EYSUVIS will complement the Systane family of eye drops which includes the recently launched Systane Preservative-Free formulations now available in a convenient, multi-dose bottle. While the Systane family is used for ongoing management of dry eye symptoms, EYSUVIS will provide Eye Care Professionals (ECPs) with an option for short-term treatment to mitigate dry eye disease.

Over 30 million people in the United States suffer from dry eye. Alcon research shows that about 20-25% of dry eye patients experience acute episodes of dry eye on average twice per year. EYSUVIS, a corticosteroid, may be prescribed by ECPs during these episodes of acute dry eye.

EYSUVIS was approved by the U.S. Food & Drug Administration in January 2021 as the first-and-only corticosteroid indicated for up to two weeks of treatment of the signs and symptoms of dry eye disease. The prescription therapy utilizes a proprietary drug delivery technology known as AMPPLIFY to enhance penetration of loteprednol etabonate into targeted tissue on the ocular surface, helping to prevent flares associated with dry eye disease.

“We will be pleased to add EYSUVIS to our growing pharmaceutical portfolio,” said Sergio Duplan, President, North America at Alcon. “EYSUVIS is a natural fit for our newly formed ophthalmic eye drop sales force in the United States. With our strong expertise in market access and commercial execution, we are well-positioned to build the market for acute dry eye treatment.”

As part of the agreement, Alcon will also acquire INVELTYS (loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery.




The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular